Proper medical oversight matters, particularly for patients with diabetes, kidney disease, history of pancreatitis, or other comorbidities
When tirzepatide activates GLP-1 receptors, it stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning insulin is released only when blood glucose levels are elevated
Other serious but rare side effects include pancreatitis, low blood sugar, gallbladder problems, kidney problems, allergies, increased heart rate, and depression or thoughts of suicide
Subscribe for evidence-based best practices and to discover the outcomes
manufacturing investment since 2020 exceeding $50 billion, news release, February 26, 2025, [164]
Fatigue or headaches Rare but can occur in individuals sensitive to peptides affecting metabolic pathways